Diagnostic Accuracy of Non-Invasive Diagnostic Tests for Nonalcoholic Fatty Liver Disease: A Systematic Review and Network Meta-Analysis

Overview

Journal Clin Epidemiol

Publisher Dove Medical Press

Date 2025 Feb 3

PMID 39897720

Authors

Yuxin Sun

Die Hu

Mingkun Yu

Shi-Bing Liang

Youyou Zheng

Xin Wang

Guangdong Tong

Affiliations

Soon will be listed here.

Abstract

Purpose: In recent decades, numerous non-invasive tests (NITs) for diagnosing nonalcoholic fatty liver disease (NAFLD) have been developed, however, a comprehensive comparison of their relative diagnostic accuracies is lacking. We aimed to assess and compare the diagnostic accuracy of various NITs for NAFLD using network meta-analysis (NMA).

Materials And Methods: We conducted a systematic search in seven databases up to April 2024 to identify studies evaluating the diagnostic values of NITs, with liver biopsy as the gold standard. The participants included patients with suspected or confirmed NAFLD, irrespective of age, sex, ethnicity. Statistical analysis was conducted using R 4.0.3 for Bayesian NMA and STATA 17.0 for pairwise meta-analysis. Sensitivity, specificity, diagnostic odds ratio (DOR), area under the receiver operating characteristic curve (AUC), and superiority index were calculated. Bayesian calculations were performed using the Rstan package, specifying parameters like MCMC chain count, iteration count, and operational cycles. The methodological quality of included studies was assessed using the QUADAS-2 tool.

Results: Out of 15,877 studies, 180 were included in the quantitative synthesis, and 102 were used in head-to-head meta-analyses. For diagnosing steatosis stage 1, Hydrogen Magnetic Resonance Spectroscopy (H-MRS, DOR 15,745,657.6, 95% CI 17.2-1,014,063.59) proved to be the most accurate. For significant fibrosis, HRI leading (DOR 80.94, 95% CI 6.46-391.41), For advanced fibrosis, CK-18 showed the highest performance (DOR 102654.16, 95% CI 1.6-134,059.8). For high-risk NASH, Real-Time Elastography showing the highest performance (DOR 18.1, 95% CI 0.7-96.33). Meta-regression analyses suggested that variability in the diagnostic accuracy of NITs for NAFLD may result from differences in study design, thresholds, populations, and performance indicators.

Conclusion: We conducted a network meta-analysis to rank the accuracy of these tests. While some results are promising, not all NITs demonstrate substantial accuracy, highlighting the need for validation with larger datasets. Future research should concentrate on studying the thresholds of NITs and enhancing the clarity of methodological reporting.

References

Nyaga V, Aerts M, Arbyn M . ANOVA model for network meta-analysis of diagnostic test accuracy data. Stat Methods Med Res. 2016; 27(6):1766-1784. DOI: 10.1177/0962280216669182. View

Kang S, Lee H, Yoo J, Cho Y, Kim S, Lee T . KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease. Clin Mol Hepatol. 2021; 27(3):363-401. PMC: 8273632. DOI: 10.3350/cmh.2021.0178. View

McInnes M, Moher D, Thombs B, McGrath T, Bossuyt P, Clifford T . Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. JAMA. 2018; 319(4):388-396. DOI: 10.1001/jama.2017.19163. View

Chow K, Futela P, Saharan A, Saab S . Comparison of Guidelines for the Screening, Diagnosis, and Noninvasive Assessment of Nonalcoholic Fatty Liver Disease. J Clin Exp Hepatol. 2023; 13(5):783-793. PMC: 10483000. DOI: 10.1016/j.jceh.2023.01.016. View

ISHAK K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F . Histological grading and staging of chronic hepatitis. J Hepatol. 1995; 22(6):696-9. DOI: 10.1016/0168-8278(95)80226-6. View

Gruneau L, Kechagias S, Sandstrom P, Ekstedt M, Henriksson M . Cost-effectiveness analysis of noninvasive tests to identify advanced fibrosis in non-alcoholic fatty liver disease. Hepatol Commun. 2023; 7(7). PMC: 10289790. DOI: 10.1097/HC9.0000000000000191. View

Hutton B, Salanti G, Caldwell D, Chaimani A, Schmid C, Cameron C . The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015; 162(11):777-84. DOI: 10.7326/M14-2385. View

Younossi Z, Pham H, Felix S, Stepanova M, Jeffers T, Younossi E . Identification of High-Risk Patients With Nonalcoholic Fatty Liver Disease Using Noninvasive Tests From Primary Care and Endocrinology Real-World Practices. Clin Transl Gastroenterol. 2021; 12(4):e00340. PMC: 8032357. DOI: 10.14309/ctg.0000000000000340. View

Younossi Z, Alkhouri N, Cusi K, Isaacs S, Kanwal F, Noureddin M . A practical use of noninvasive tests in clinical practice to identify high-risk patients with nonalcoholic steatohepatitis. Aliment Pharmacol Ther. 2022; 57(3):304-312. DOI: 10.1111/apt.17346. View

10.

Fouad Y, Esmat G, Elwakil R, Zakaria S, Yosry A, Waked I . The egyptian clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Saudi J Gastroenterol. 2022; 28(1):3-20. PMC: 8919931. DOI: 10.4103/sjg.sjg_357_21. View

11.

Glas A, Lijmer J, Prins M, Bonsel G, Bossuyt P . The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol. 2003; 56(11):1129-35. DOI: 10.1016/s0895-4356(03)00177-x. View

12.

Rinella M, Neuschwander-Tetri B, Siddiqui M, Abdelmalek M, Caldwell S, Barb D . AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023; 77(5):1797-1835. PMC: 10735173. DOI: 10.1097/HEP.0000000000000323. View

13.

Desmet V, Gerber M, Hoofnagle J, Manns M, Scheuer P . Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology. 1994; 19(6):1513-20. View

14.

Li G, Zhang X, Lin H, Liang L, Wong G, Wong V . Non-invasive tests of non-alcoholic fatty liver disease. Chin Med J (Engl). 2022; 135(5):532-546. PMC: 8920457. DOI: 10.1097/CM9.0000000000002027. View

15.

Man S, Deng Y, Ma Y, Fu J, Bao H, Yu C . Prevalence of Liver Steatosis and Fibrosis in the General Population and Various High-Risk Populations: A Nationwide Study With 5.7 Million Adults in China. Gastroenterology. 2023; 165(4):1025-1040. DOI: 10.1053/j.gastro.2023.05.053. View

16.

Francque S, Lanthier N, Verbeke L, Reynaert H, Van Steenkiste C, Vonghia L . The Belgian Association for Study of the Liver Guidance Document on the Management of Adult and Paediatric Non-Alcoholic Fatty Liver Disease. Acta Gastroenterol Belg. 2018; 81(1):55-81. View

17.

Bedossa P, Poynard T . An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996; 24(2):289-93. DOI: 10.1002/hep.510240201. View

18.

Shah A, Lydecker A, Murray K, Tetri B, Contos M, Sanyal A . Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009; 7(10):1104-12. PMC: 3079239. DOI: 10.1016/j.cgh.2009.05.033. View

19.

Whiting P, Rutjes A, Westwood M, Mallett S, Deeks J, Reitsma J . QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011; 155(8):529-36. DOI: 10.7326/0003-4819-155-8-201110180-00009. View

20.

Tilg H, Adolph T, Moschen A . Multiple Parallel Hits Hypothesis in Nonalcoholic Fatty Liver Disease: Revisited After a Decade. Hepatology. 2020; 73(2):833-842. PMC: 7898624. DOI: 10.1002/hep.31518. View